XSTO
IRLABa
Market cap26mUSD
Oct 09, Last price
1.71SEK
1D
-6.04%
1Q
22.14%
IPO
-97.09%
Name
IRLAB Therapeutics AB
Chart & performance
P/E
—
P/S
4.36
EPS
—
Div yield, %
—
Shrs. gr., 5y
7.04%
Rev. gr., 5y
186.06%
Revenues
57m
-39.28%
Net income
-110m
L+32.34%
CFO
-55m
L-15.81%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat, which is undergoing phase IIb clinical trials for the management of postural dysfunction. In the preclinical phase, IRLAB is advancing research programs like IRL942 and 1009, aimed at neurodegenerative conditions and the aging process, as well as IRL757, designed to alleviate apathy in various neurological disorders. Additionally, the company is conducting a research project, P003, focused on creating new therapies for individuals with a recent Parkinson's disease diagnosis. IRLAB Therapeutics AB (publ) was founded in 2013 and has its headquarters in Gothenburg, Sweden.
Key people
Maria Jalmelid
Director of Clinical Operations · since 2018
Independent Vice Chairman of the Board · since 2019
Gunnar Olsson
Independent Director · since 2017
Lena Torelgard
Independent Director · since 2018
John D. Wakely
Independent Director · since 2018
Headquarters & legal address
Arvid Wallgrens backe 20
Göteborg, O 413 46
SE
Göteborg, O 413 46
SE
Address
Arvid Wallgrens backe 20
Goteborg, O 413 46
SE
Goteborg, O 413 46
SE
Previous name
Grundbulten 6610 AB
Previous name
Integrative Invest AB
Previous name
Integrative Research Laboratories Holding AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||